October 23, 2024
The US Food and Drug Administration (FDA) has placed a partial clinical hold on the phase 3 PRESERVE-003 trial of BNT316/ONC-392 (gotistobart, BioNTech and OncoC4) for […]
October 23, 2024
TOPLINE: Compared with six cycles, three cycles of chemotherapy for high-risk retinoblastoma showed noninferior 5-year disease-free survival (DFS). The three-cycle regimen also resulted in fewer adverse […]
October 22, 2024
Many patients use cannabis to manage their cancer-related symptoms. However, research indicates that patients often do so without speaking to their oncologist first, and oncologists may […]
October 22, 2024
TOPLINE: Patients with early-stage triple-negative breast cancer (TNBC) and high immune infiltration showed improved disease-free survival (DFS) with adjuvant capecitabine. These “immune-hot” patients had a 5-year […]
October 21, 2024
TOPLINE: The Fracture Risk Assessment Tool (FRAX), with bone mineral density, predicts the risk for major osteoporotic fractures and hip fractures in patients with cancer, but […]
October 21, 2024
TOPLINE: Better pre-diagnosis dietary quality is linked to improved survival in Black women with high-grade serous ovarian cancer (HGSOC). No significant survival association was found among […]
October 18, 2024
The US Food and Drug Administration (FDA) has approved zolbetuximab (Vyloy, Astellas Pharma) in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally […]
October 18, 2024
Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Eltrombopag Viatris (eltrombopag), a generic medicine for the treatment of […]
October 18, 2024
In its October 2024 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave the green light for Korjuny (catumaxomab, Lindis […]